Nucleic Acid Synthesis Inhibitors

Nucleoside Metabolic Inhibitor

Myelodysplastic Syndromes

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-9"></a><h1>11 DESCRIPTION</h1>DecitabineDecitabine is a nucleoside metabolic inhibitor. Decitabine is a white to off-white solid with the molecular formula of C8H12N4O4 and a molecular weight of 228.21 daltons. Its international union of pure and applied chemistry (IUPAC) chemical name is 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2(1H)-one and it has the following structural formula:<div class="Figure"><img alt="Chemical Structure" src="inqovi-02.jpg"/></div>CedazuridineCedazuridine is a cytidine deaminase inhibitor. Cedazuridine is a white to off-white solid with the molecular formula of C9H14F2N2O5 and a molecular weight of 268.21 daltons. Its IUPAC chemical name is (4R)-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one and it has the following structural formula:<div class="Figure"><img alt="Chemical Structure" src="inqovi-01.jpg"/></div>INQOVIINQOVI (decitabine and cedazuridine) tablets, for oral use contain 35 mg decitabine and 100 mg cedazuridine. The tablets are biconvex, oval-shaped, film-coated, red and debossed with “H35” on one side. Each film-coated tablet contains the following inactive ingredients: lactose monohydrate, hypromellose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. The film coating material contains polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and iron oxide red.</section>

INQOVI

decitabine

cedazuridine

cedazuridine / decitabine

cedazuridine 100 MG / decitabine 35 MG Oral Tablet

Inqovi

cedazuridine 100 MG / decitabine 35 MG Oral Tablet [Inqovi]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Prescribing Information - Spanish 

Medication Guide 

Medication Guide - Spanish

Submit MSL Request 

Pharmacy List 

Billing & Coding Guide 

How To Order Inqovi

Inqovi Enrollment Form 

Inqovi Enrollment Form - Spanish 

Tahio HCP Portal 

Coverage Authorization Request 

Coverage Authorization Appeals 

Enroll In Patient Savings Program 

Other HCP Resources

Caregiver Brochure 

Patient Brochure 

Patient Access Brochure 

Co-Pay Brochure 

About Inqovi 

Taking Inqovi 

Side Effects 

Patient Resources 

Instructions For Use: Myelodysplastic Syndromes

Taiho Oncology Patient Support